Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.
Mertens, Fredrik LU ; Antonescu, Cristina R and Mitelman, Felix LU
(2016)
In Genes, Chromosomes and Cancer
55(4).
p.291-310
- Abstract
- Gene fusions have been described in approximately one-third of soft tissue tumors (STT); of the 142 different fusions that have been reported, more than half are recurrent in the same histologic subtype. These gene fusions constitute pivotal driver mutations, and detailed studies of their cellular effects have provided important knowledge about pathogenetic mechanisms in STT. Furthermore, most fusions are strongly associated with a particular histotype, serving as ideal molecular diagnostic markers. In recent years, it has also become apparent that some chimeric proteins, directly or indirectly, constitute excellent treatment targets, making the detection of gene fusions in STT ever more important. Indeed, pharmacological treatment of STT... (More)
- Gene fusions have been described in approximately one-third of soft tissue tumors (STT); of the 142 different fusions that have been reported, more than half are recurrent in the same histologic subtype. These gene fusions constitute pivotal driver mutations, and detailed studies of their cellular effects have provided important knowledge about pathogenetic mechanisms in STT. Furthermore, most fusions are strongly associated with a particular histotype, serving as ideal molecular diagnostic markers. In recent years, it has also become apparent that some chimeric proteins, directly or indirectly, constitute excellent treatment targets, making the detection of gene fusions in STT ever more important. Indeed, pharmacological treatment of STT displaying fusions that activate protein kinases, such as ALK and ROS1, or growth factors, such as PDGFB, is already in clinical use. However, the vast majority (52/78) of recurrent gene fusions create structurally altered and/or deregulated transcription factors, and a small but growing subset develops through rearranged chromatin regulators. The present review provides an overview of the spectrum of currently recognized gene fusions in STT, and, on the basis of the protein class involved, the mechanisms by which they exert their oncogenic effect are discussed. © 2015 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8504184
- author
- Mertens, Fredrik
LU
; Antonescu, Cristina R
and Mitelman, Felix
LU
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Genes, Chromosomes and Cancer
- volume
- 55
- issue
- 4
- pages
- 291 - 310
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:26684580
- scopus:84958750762
- wos:000370168100001
- pmid:26684580
- ISSN
- 1045-2257
- DOI
- 10.1002/gcc.22335
- language
- English
- LU publication?
- yes
- id
- e03022e0-c089-42fd-a278-152dbc14cd3c (old id 8504184)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26684580?dopt=Abstract
- date added to LUP
- 2016-04-04 07:06:20
- date last changed
- 2022-06-11 05:33:12
@article{e03022e0-c089-42fd-a278-152dbc14cd3c,
abstract = {{Gene fusions have been described in approximately one-third of soft tissue tumors (STT); of the 142 different fusions that have been reported, more than half are recurrent in the same histologic subtype. These gene fusions constitute pivotal driver mutations, and detailed studies of their cellular effects have provided important knowledge about pathogenetic mechanisms in STT. Furthermore, most fusions are strongly associated with a particular histotype, serving as ideal molecular diagnostic markers. In recent years, it has also become apparent that some chimeric proteins, directly or indirectly, constitute excellent treatment targets, making the detection of gene fusions in STT ever more important. Indeed, pharmacological treatment of STT displaying fusions that activate protein kinases, such as ALK and ROS1, or growth factors, such as PDGFB, is already in clinical use. However, the vast majority (52/78) of recurrent gene fusions create structurally altered and/or deregulated transcription factors, and a small but growing subset develops through rearranged chromatin regulators. The present review provides an overview of the spectrum of currently recognized gene fusions in STT, and, on the basis of the protein class involved, the mechanisms by which they exert their oncogenic effect are discussed. © 2015 Wiley Periodicals, Inc.}},
author = {{Mertens, Fredrik and Antonescu, Cristina R and Mitelman, Felix}},
issn = {{1045-2257}},
language = {{eng}},
number = {{4}},
pages = {{291--310}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Genes, Chromosomes and Cancer}},
title = {{Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.}},
url = {{http://dx.doi.org/10.1002/gcc.22335}},
doi = {{10.1002/gcc.22335}},
volume = {{55}},
year = {{2016}},
}